Summary
SLC6A1-Neurodevelopmental Disorder (NDD) is a rare genetic condition caused by changes (variants) in the SLC6A1 gene. This gene makes a protein that helps control the amount of a chemical in the brain (neurotransmitter) called GABA. This neurotransmitter works to balance the excitement activity between neurons (communication cells in the brain). When the SLC6A1 gene doesn’t work properly, it can lead to seizures, developmental delays, autism spectrum disorder, movement problems, and learning difficulties. Symptoms can usually be seen in toddlers and sometimes in infants. While there is no cure, treatments like medications and therapy can help manage symptoms.
Description
In SLC6A1-NDD, the protein that the SLC6A1 gene makes does not function the way it should. The protein cleans up extra GABA (a calming brain chemical), moving it into neurons where it can be used. In a healthy brain, GABA stops neurons from over-firing, preventing seizures and helping with learning and movement. When this process is disrupted, the brain becomes overactive, causing seizures and developmental challenges.
There are symptoms of SLC6A1-NDD that we can expect, but the severity of those symptoms can vary widely, and not every symptom will occur in every child. Some children have mild delays and rare seizures, while others face severe epilepsy, significant intellectual disability, and trouble walking or talking. Children should be tested for autism spectrum disorder, monitored for behavior and mood problems, and caregivers should be asked about sleep and stomach issues. The disorder is not typically fatal, but poorly controlled seizures can be dangerous.
Signs and Symptoms
- Diagnosis is confirmed by genetic testing. Key symptoms include:
- Epilepsy: Seizures often start before age 3 (can look like staring and/or blinking, sudden unexplained falls, jerking of one part of the body, shaking of the whole body).
- Developmental delays: Late walking, talking, or learning skills.
- Autism Spectrum Disorder: Range from low support needs to high support needs, unusual or underdeveloped social skills
- Movement issues: Poor coordination, muscle stiffness, or tremors.
- Intellectual disability: Mild to severe learning challenges.
- Behavioral traits: Hyperactivity, autism-like behaviors, anxiety, trouble regulating emotions.
- Subtle early signs might include delayed crawling, weak muscles as young babies, or mild speech delays. Seizures are often the first noticeable symptom. Over time, learning and movement difficulties become more apparent.
Causes
- SLC6A1-NDD is caused by random genetic changes (variants) in the SLC6A1 gene.
- Most cases are not inherited, but the mutation can very rarely be passed from a parent who carries it in some cells (mosaicism).
- The change in the gene is not caused by environmental exposures or anything parents have done or didn’t do. The change occurs at the earliest stage of conception.
Laboratory Investigations
Genetic testing
Whole exome sequencing or targeted gene panels to find SLC6A1 variants.
EEG
Detects abnormal brain activity linked to seizures.
MRI
Usually normal but occasionally can have changes in the structure of the brain.
Genetic testing is done once, but EEGs may be repeated to monitor seizures.
Resources
SLC6A1 Connect is a patient advocacy group dedicated to improving the lives of children and families affected by SLC6A1.
Our focus is to raise awareness and fundraising to advance scientific research that will ultimately result in a cure.
The links and resources included in this section are solicited directly from the community by the Child Neurology Foundation through a formal submission process. CNF reserves the right to remove entities at any time if information is deemed inappropriate or inconsistent with the mission, vision, and values of CNF. The authors listed on this page have not endorsed the resources or links provided in this section.
Research
ClinicalTrials.gov for SLC6A1 (birth to 17 years)
These are clinical trials that are recruiting or will be recruiting. Updates are made daily, so you are encouraged to check back frequently.
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. This is a resource provided by the U.S. National Library of Medicine (NLM), which is an institute within the National Institutes of Health (NIH). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Please read the NLM disclaimer for details.
Before participating in a study, you are encouraged to talk to your health care provider and learn about the risks and potential benefits.
For more information about participation in clinical trials, check out our education hub on the topic here.
Family Stories
The information in the CNF Child Neurology Disorder Directory is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only. CNF is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options.
References
- Goodsell DS, Mattison KA, Johannesen KM, et al. Current knowledge of SLC6A1-related neurodevelopmental disorders. Front Neurosci. 2020 Oct 13;14:598801. doi:10.3389/fnins.2020.598801. PMID: 33192681; PMCID: PMC7677605. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7677605/
- Johannesen KM, Gardella E, Rubboli G, et al. Behavioral, neurodevelopmental profile, and epilepsy trajectory in SLC6A1-related neurodevelopmental disorders. Eur J Paediatr Neurol. 2025 Jan;47:1-10. doi:10.1016/j.ejpn.2024.105539. PMID: 39889538. Available from: https://pubmed.ncbi.nlm.nih.gov/39889538/
- Pizzo F, Gennaro E, Gennaro G, et al. Intrafamilial variability in SLC6A1-related neurodevelopmental disorders. Front Neurol. 2023 Jul 12;14:1205532. doi:10.3389/fneur.2023.1205532. PMID: 37500379; PMCID: PMC10368872. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10368872/
- Verhoeven WM, Egger JIM, Egger J, et al. Insights into cognitive and behavioral comorbidities of SLC6A1-related neurodevelopmental disorders. Front Neurol. 2023 Aug 28;14:1216653. doi:10.3389/fnins.2023.1216653. PMID: 37692421; PMCID: PMC10493279. Available from: https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1216653/full
- Johannesen KM, Rubboli G, Gardella E, et al. The phenotypic presentation of adult individuals with SLC6A1-related neurodevelopmental disorders. Front Neurol. 2023 Aug 17;14:1216653. doi:10.3389/fneur.2023.1216653. PMID: 37692421; PMCID: PMC10472133. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10472133/
- Perplexity AI, Inc. Perplexity [Internet]. San Francisco (CA): Perplexity AI, Inc.; 2025 [cited 2025 Oct 24]. Available from: https://www.perplexity.ai
This overview is for general information and is not a substitute for advice from your child's care team.
← Back to the Disorder Directory